Huh? Where is the big double top pattern, Lionel?

Strong closing for GenS today.

LKT bought again on the ex date itself. Hopefully there will be good news in Apr.

Ooh I got it now. Its much clearer. Your concern is on LKT buying now and then issue new shares later? There is no straight forward answers unfortunately. Respective shareholders will have to go through the details if there is such situation and make a decision thereafter. Things like reasons for issuance of new shares, the subtle balance between debt and equity, the timing which typically coincide with favourable market conditions and etc. Personally for me, from valuation perspective, issuing new shares when share price is at low valuation will be detrimental to investors confidence - eps dilution and will trigger market rerating.

you will also notice how comments change according to the market force :) One moment negative another moment positive. Lol, no pun intended. Just enjoy the volatility driven by market force. After all, the market force carries with it the actions, motivations and sometimes flaws of every participant as the saying goes.

I am not sure whether I understood the translation correctly, kok. The translation is as such "I hope I won't misunderstand him. If he engages in private or surcharge, I will really be sorry to the majority of investors". If you are referring to market force, no BODs will have controls over it. everyone just need to manage their own positions accordingly.

20th floor incoming?

stay disciplined and risk only small % of capital :)

stay above ipo price at level 3++ until the next qr is out.

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision not to recommend the Alzheimer’s treatments Kisunla (donanemab) and Leqembi (lecanemab) for use on the National Health Service (NHS) in England.
This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a negative coverage decision for Eli Lilly’s Kisunla came in October 2024.
Following a request for additional evidence, NICE’s independent appraisal committee reviewed new data but maintained its stance that the medicines are not cost-effective. NICE stated that neither treatment provides sufficient benefit to justify the significant cost of provision and administration within the NHS.

The committee concluded that even under a managed access arrangement – where drugs are provided at a discounted price for a fixed period while additional evidence is collected – was not acceptable. “The cost-effectiveness estimates for donanemab and lecanemab remain substantially higher than we can consider an acceptable use of taxpayers’ money and NHS resources,” said NICE in the 6 March announcement.

The draft guidance has now been opened for public consultation, which will close on 27 March 2025, after which NICE will convene a third appraisal meeting to consider responses before issuing final recommendations. Kisunla and Leqembi are both monoclonal antibodies designed to slow early cognitive decline in Alzheimer’s patients by targeting amyloid beta plaques in the brain. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved both treatments in 2024, becoming the first regulatory agency to do so.